Luc Furic

13PUBLICATIONS
54CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 08, 2026
Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.

|Jun 19, 2026
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

|Nov 19, 2025
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Sehrish Kanwal, Natalie Brajanovski, Jiajun Zhan

|Aug 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

Gail P Risbridger, Ashlee K Clark, Laura H Porter

|Aug 20, 2021
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.

Mitchell G Lawrence, Laura H Porter, Nicholas Choo

|Jul 02, 2021
Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer.

Jianling Xie, Eric P Kusnadi, Luc Furic

Pageof 3

Frequent Collaborators

2 joint publications

Luke A Selth

2 joint publications

Richard B Pearson

2 joint publications

Laura H Porter

2 joint publications

Lisa Devereux